scholarly journals Quality of life, depressive symptoms, anxiety, and sexual function in mothers of neonates with congenital syphilis in the Northeast Brazil: A cohort study

2022 ◽  
Vol 7 ◽  
pp. 100127
Author(s):  
Carolina Santos Souza Tavares ◽  
Sheila Jaqueline Gomes dos Santos Oliveira ◽  
Vanessa Tavares de Gois-Santos ◽  
Andreia Centenaro Vaez ◽  
Max Oliveira de Menezes ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cohort Study ◽  
Depressive Symptoms ◽  
Sexual Function ◽  
Congenital Syphilis ◽  
Northeast Brazil

Lifestyle and outcomes after gastrointestinal cancer: A prospective cohort study (LOGIC).

2018 ◽  
Vol 36 (7_suppl) ◽  
pp. 180-180
Author(s):  
Marissa Barbara Savoie ◽  
Katherine Van Loon ◽  
Angela Laffan ◽  
Andrea Grace Bocobo ◽  
Li Zhang ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cohort Study ◽  
Sexual Function ◽  
Cancer Recurrence ◽  
Well Being ◽  
Fear Of Cancer Recurrence ◽  
Psychological Well Being ◽  
Gi Cancer ◽  
Gi Cancers

180 Background: The number of individuals living after a diagnosis of gastrointestinal (GI) cancer is increasing. Emerging data suggest modifiable lifestyle factors impact survival after colorectal cancer (CRC), however very little is known about survivorship in other GI cancers. Given the common thread of multimodality therapy among many GI cancer survivors, there is a paucity of data on sexual function, fertility, anxiety/depression, changes in comorbidities, and quality of life after cancer treatment. Additionally, existing cohort studies of GI survivors are primarily European, and further data are needed from survivor populations in the US . Methods: Patients of the University of California, San Francisco GI Oncology Survivorship Clinic who are designated disease-free are recruited by mail or in clinic. We send secure online questionnaires to participants every six months for five years and annually thereafter. At varying intervals, questionnaires solicit sociodemographics, diet, physical activity, fertility, medical and smoking history, fear of cancer recurrence, sexual health, quality of life, psychological well-being, and sleep quality. Pathoclinical disease characteristics, treatment, and recurrence status are abstracted from the medical record at baseline and updated annually. Results: Between February and August 2017, 111 patients were enrolled; 68% of participants completed ≥1 and 57% completed all baseline questionnaires. Most patients had a history of colon cancer (52%, n = 58) or rectal cancer (31%, n = 34). Other diseases include: anal cancer (12%, n = 13), gastrointestinal stromal tumor (3%, n = 3), and other GI cancers (3%, n = 3). Fifty-eight percent of patients were female, 76% identified as white and median age at diagnosis was 55 (range 20-81). Median time from initial GI cancer diagnosis to study entry was 27 months. Following the initial recruitment wave of established patients, the average rate of enrollment is ~3 patients/week. Conclusions: Results from this ongoing cohort study will improve our understanding of modifiable risk factors for GI cancer recurrence and key survivorship issues related to psychological well-being, sexual function, fertility management, and quality of life.

scholarly journals Sexual function, quality of life, and fertility in women who had surgery for neonatal Hirschsprung’s disease

2021 ◽  
Author(s):  
J R Davidson ◽  
K Kyrklund ◽  
S Eaton ◽  
M P Pakarinen ◽  
D S Thompson ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cohort Study ◽  
Sexual Function ◽  
Hirschsprung's Disease ◽  
Hirschsprung’S Disease ◽  
Cross Sectional ◽  
Female Patients

The authors explore multi-domain outcomes in a cross-sectional cohort study of patients with Hirschsprung's Disease. They identify hitherto unrecognised issues affecting sexual function and fertility specifically in female patients.

scholarly journals Depressive symptoms and quality of life after screening for cognitive impairment in patients with type 2 diabetes: observations from the Cog-ID cohort study

BMJ Open ◽  
2019 ◽  
Vol 9 (1) ◽  
pp. e024696 ◽  
Author(s):  
Jolien Janssen ◽  
Paula S Koekkoek ◽  
Geert-Jan Biessels ◽  
Jaap L Kappelle ◽  
Guy E H M Rutten
Keyword(s):  
Quality Of Life ◽  
Type 2 Diabetes ◽  
Cohort Study ◽  
Cognitive Impairment ◽  
Depressive Symptoms ◽  
Short Form ◽  
Depression Scale ◽  
Analysis Of Covariance

ObjectivesTo assess changes in depressive symptoms and health-related quality of life (HRQOL) after screening for cognitive impairment in people with type 2 diabetes.DesignA prospective cohort study, part of the Cognitive Impairment in Diabetes (Cog-ID) study.SettingParticipants were screened for cognitive impairment in primary care. People suspected of cognitive impairment (screen positives) received a standardised evaluation at a memory clinic.ParticipantsParticipants ≥70 years with type 2 diabetes were included in Cog-ID between August 2012 and September 2014, the current study includes 179 patients; 39 screen positives with cognitive impairment, 56 screen positives without cognitive impairment and 84 participants not suspected of cognitive impairment during screening (screen negatives).Outcome measuresDepressive symptoms and HRQOL assessed with the Center for Epidemiologic Studies Depression Scale (CES-D), 36-Item Short-Form Health Survey, European Quality of Life-5 Dimensions questionnaire and the EuroQol Visual Analogue Scale. Outcomes were assessed before the screening, and 6 and 24 months after screening. An analysis of covariance model was fitted to assess differences in score changes among people diagnosed with cognitive impairment, screen negatives and screen positives without cognitive impairment using a factor group and baseline score as a covariate.ResultsOf all participants, 60.3% was male, mean age was 76.3±5.0 years, mean diabetes duration 13.0±8.5 years. At screening, participants diagnosed with cognitive impairment had significantly more depressive symptoms and a worse HRQOL than screen negatives. Scores of both groups remained stable over time. Screen positives without cognitive impairment scored between the other two groups at screening, but their depressive symptoms decreased significantly during follow-up (mean CES-D: −3.1 after 6 and −2.1 after 24 months); their HRQOL also tended to improve.ConclusionsDepressive symptoms are common in older people with type 2 diabetes. Screening for and a subsequent diagnosis of cognitive impairment will not increase depressive symptoms.

scholarly journals Post-discharge depressive symptoms can predict quality of life in AMI survivors: A prospective cohort study in Japan

2011 ◽  
Vol 146 (3) ◽  
pp. 379-384 ◽  
Author(s):  
Michi Sakai ◽  
Takeo Nakayama ◽  
Takuro Shimbo ◽  
Kenji Ueshima ◽  
Noboru Kobayashi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cohort Study ◽  
Depressive Symptoms ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Post Discharge

scholarly journals 1716. Prospective Multicenter Observational Cohort Study to Assess the Burden of Herpes Zoster Disease in the Eye: Baseline Results of Initial Patients

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S841-S842
Author(s):  
Laura T Pizzi ◽  
Benjamin Leiby ◽  
David S Chu ◽  
Emily W Gower ◽  
Haresh Ailani ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cohort Study ◽  
Depressive Symptoms ◽  
Herpes Zoster ◽  
Observational Cohort Study ◽  
Patient Reported ◽  
Related Quality ◽  
Observational Cohort ◽  
The Mean

Abstract Background Herpes Zoster Ophthalmicus (HZO) affects 10-20% of adults with herpes zoster; ≥ 50% of these cases manifest as serious ocular diseases. This 1-year prospective observational cohort study aims to determine patient-reported HZO symptoms as well as economic and quality of life burden among 300 HZO patients from 6 major US ophthalmology practices. Here, we report baseline data from 13 initial enrollees. Methods Inclusion criteria were: participants ≥ 18 years, diagnosis of clinically active HZO, English or Spanish speaking, be willing and able to respond to study assessments, not be enrolled in a concurrent interventional HZO trial. Information are collected via 1) a clinical assessment form completed by the practice (baseline) and 2) patient questionnaires (baseline, 3, 6, and 12 months) on symptoms, medications, healthcare use, vision function, depression, and work productivity impact. Baseline results are presented for patients recruited during the first 6 months of enrollment from the first 4 sites to go live: diagnoses, and patient-reported symptoms and outcomes (eight-item Patient Health Questionnaire [PHQ-8] for depressive symptoms, National Eye Institute 25-item Visual Function Questionnaire [NEI-VFQ-25] for vision-related quality of life, and Zoster Brief Pain Inventory [ZBPI] for pain). Results The mean age of participants is 71 years; 11 are female and 9 are retired. Seven participants are college graduates or hold other degrees. All have health insurance coverage, with most (10) having primary insurance through Medicare. HZO diagnoses (Table 1) were: keratitis (4), iridocyclitis (4), conjunctivitis (1), other HZO diagnosis (3), other ocular diagnosis (6). Patient-reported symptoms (Table 2) were: pain above the eye, sensitivity to light, redness, feeling of sand/grit in the eye (9 each). The mean overall PHQ-8 and NEI-VFQ-25 scores were 5.9 (Standard Deviation [SD]:4.5) and 74.6 (SD:13.9), respectively; the mean ZBPI score for worst pain severity was 3.3 (SD:3.8) (Table 3). Table 1. HZO Diagnosis at Baseline based on Clinical Assessment Form (N=13) Table 2. Patient-reported Symptoms in the HZO-Affected Eye at Baseline (N=13) Table 3. Patient-reported Outcomes: Depressive Symptoms, Vision-Related Quality of Life, and Herpes Zoster Pain at Baseline (N=13) Conclusion This study represents the first large scale effort to quantify HZO burden. Findings will inform development of a formal patient-reported symptom scale for use in research and clinical practice. Funding GlaxoSmithKline Biologicals SA (GSK study identifiers: 209235/HO-17-17967) Disclosures Laura T. Pizzi, PharmD, MPH, ORCID: 0000-0002-7366-7661, GlaxoSmithKline (Research Grant or Support) Soham Shukla, PharmD, ORCID: 0000-0002-4139-0856, GSK (Employee)Rutgers University (Employee) Brandon J. Patterson, PharmD, PhD, GSK (Employee, Shareholder) Debora A. Rausch, MD, ORCID: 0000-0001-9759-2687, GSK (Employee) Philip O. Buck, PhD, MPH, ORCID: 0000-0002-3898-3669, GSK (Employee, Shareholder) Ann P. Murchison, MD, MPH, GSK (Grant/Research Support)

Sign in / Sign up

Export Citation Format

Share Document